Infectious complications of stem cell transplantation.

Cancer Treat Res

Department of Medicine, The University of Chicago Hospitals, 5841 South Maryland Avenue, MC 5065, Chicago, IL, 60637, USA, http://dx.doi.org/10.1007/978-3-319-04220-6_12DOI Listing

Publication Analysis

Top Keywords

stem cell
8
cell transplantation
8
infectious complications
4
complications stem
4
transplantation hematopoietic
4
hematopoietic stem
4
transplantation hsct
4
hsct accepted
4
accepted treatment
4
treatment variety
4

Similar Publications

Autologous hematopoietic stem cell transplantation is used to restore bone marrow function after high-dose chemotherapy. For apheresis, granulocyte colony-stimulating factor (G-CSF) is standard of care, but obtaining sufficient stem cells can be challenging. Other mobilization agents include plerixafor and PEGylated G-CSF (PEG-G-CSF).

View Article and Find Full Text PDF

Acute inflammation induces acute megakaryopoiesis with impaired platelet production during fetal hematopoiesis.

Development

January 2025

Institute for Regenerative Medicine, State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.

Hematopoietic development is tightly regulated by various factors. The role of RNA m6A modification during fetal hematopoiesis, particularly in megakaryopoiesis, remains unclear. Here, we demonstrate that loss of m6A methyltransferase METTL3 induces formation of double-stranded RNAs (dsRNAs) and activates acute inflammation during fetal hematopoiesis.

View Article and Find Full Text PDF

Invasive pulmonary infections are a significant cause of morbidity and mortality in patients with hematological malignancies and hematopoietic stem cell transplantation (HCT) recipients. A delay in identifying a causative agent may result in late initiation of appropriate treatment and adverse clinical outcomes. We examine the diagnostic utility of PCR-based assays in evaluating invasive pulmonary infections from bronchoalveolar lavage (BAL).

View Article and Find Full Text PDF

Tamoxifen (TAM) is employed to treat premenopausal ER-positive breast cancer patients, but TAM resistance is the main reason affecting its efficacy. Thus, addressing TAM resistance is crucial for improving therapeutic outcomes. This study explored the potential role of Tinagl1, a secreted extracellular matrix protein, whose expression is compromised in TAM-resistant MCF-7 breast cancer cells (MCF-7R).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!